Abstract: This application relates to effector controlled eukaryotic expression vectors adapted for use in gene therapy or gene immunization having positive feedback regulation.
Abstract: Disclosed are methods of reducing neovascularization and of treating various disorders associated with neovascularization. These methods include administering to a tissue or subject a synthetic oligonucleotide specific for vascular endothelial growth factor nucleic acid effective in inhibiting the expression of vascular endothelial growth factor.
Type:
Grant
Filed:
July 12, 1995
Date of Patent:
September 1, 1998
Assignee:
Hybridon, Inc.
Inventors:
Gregory S. Robinson, Lois Elaine Hodgson Smith
Abstract: A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol.
Abstract: Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.
Type:
Grant
Filed:
February 1, 1996
Date of Patent:
July 21, 1998
Assignee:
Genzyme Corporation
Inventors:
Edward R. Lee, David J. Harris, Craig S. Siegel, Seng H. Cheng, Simon J. Eastman, John Marshall, Ronald K. Scheule
Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
May 5, 1998
Assignees:
Myraid Genetics, Inc., University of Utah Research Foundation, The United States of America as represented by the Secretary of Health and Human Services
Inventors:
Mark H. Skolnick, David E. Goldgar, Yoshio Miki, Jeff Swenson, Alexander Kamb, Keith D. Harshman, Donna M. Shattuck-Eidens, Sean V. Tavtigian, Roger W. Wiseman, P. Andrew Futreal